NasdaqGM:VITL
NasdaqGM:VITLFood

August 2025 Growth Stocks With Strong Insider Ownership

As of August 2025, the U.S. stock market is experiencing a downturn with major indices like the S&P 500 and Nasdaq Composite declining due to a slump in technology stocks, while investors await guidance from Federal Reserve Chair Jerome Powell regarding interest rates. In this environment of uncertainty, growth companies with high insider ownership often stand out as potentially resilient investments, as substantial insider stakes can indicate confidence in the company's long-term prospects...
NasdaqGM:VNDA
NasdaqGM:VNDABiotechs

3 Promising Penny Stocks With Over $90M Market Cap

As the U.S. stock market experiences a downturn with the S&P 500 declining for a fourth consecutive day, investors are keenly focused on upcoming signals from Federal Reserve Chair Jerome Powell regarding interest rates. In such fluctuating market conditions, penny stocks—often representing smaller or less-established companies—remain an intriguing investment area due to their potential for substantial growth. By identifying those with strong financial foundations and promising growth...
NYSE:AR
NYSE:AROil and Gas

Will Antero Resources' (AR) Leadership Overhaul Reshape Its Long-Term Strategy and Corporate Governance?

On August 14, 2025, Antero Resources Corporation and Antero Midstream Corporation announced a leadership transition, with Michael N. Kennedy promoted to Chief Executive Officer and President, and Co-Founder Paul M. Rady moving to Chairman Emeritus; Brendan E. Krueger was named Chief Financial Officer, and the roles of Chairman of the Board and CEO were separated, with Benjamin A. Hardesty appointed as Chairman of Antero Resources. This shift marks a significant update to Antero's executive...
NasdaqGS:SYBT
NasdaqGS:SYBTBanks

Stock Yards Bancorp's Dividend Increase: Reaffirming Conviction or Signaling a Shift for SYBT?

On August 20, 2025, Stock Yards Bancorp, Inc. announced its board of directors raised the quarterly cash dividend to $0.32 per common share, payable October 1, 2025, to shareholders of record as of September 15, 2025. This dividend increase reflects management’s conviction in the company’s underlying financial strength and can enhance its appeal to income-focused investors. We'll examine how the dividend hike underscores Stock Yards Bancorp’s commitment to shareholder returns and shapes its...
NYSE:VYX
NYSE:VYXSoftware

NCR Voyix (VYX) Reaffirms Revenue Guidance as Losses Narrow—Is the Digital Turnaround Taking Hold?

NCR Voyix Corporation recently announced its second quarter 2025 earnings, reporting revenue of US$666 million versus US$722 million a year earlier and a narrowed quarterly loss, while maintaining its full-year revenue guidance of US$1.995 billion to US$2.02 billion. Despite a year-over-year revenue decline, the company reduced its net losses and reaffirmed its outlook, signaling potential progress in operational efficiency during a period of continued business transformation. We'll examine...
NYSE:CNC
NYSE:CNCHealthcare

How Court Rulings on Medicare Drug Pricing May Impact Centene’s Current Valuation

Are you wondering whether now is the right time to jump into Centene stock, or if it is better to sit tight given the recent market noise? Investors have been eyeing CNC shares closely as the healthcare sector continues to ride out policy changes and market shifts. Over the past month, Centene’s share price has climbed more than 7%, shrugging off a rocky 90-day stretch where the stock fell nearly 5%. It is a resilient showing, especially considering the year-to-date returns are still down...
NasdaqGM:RNA
NasdaqGM:RNABiotechs

Did Avidity's (RNA) $620 Million Lonza Deal and Steep Q2 Loss Just Shift Its Investment Narrative?

Avidity Biosciences recently reported its second quarter 2025 earnings, revealing a net loss of US$157.32 million and basic loss per share from continuing operations of US$1.21, both higher than for the same period last year. Avidity also entered into a multi-year manufacturing agreement with Lonza, committing to purchase approximately US$620 million in drug products between 2026 and 2028 to support future commercial plans. We'll explore how Avidity's major manufacturing commitment with...
NYSE:DOV
NYSE:DOVMachinery

Dover (DOV): Fresh Look at Valuation Following Ongoing Share Weakness

Dover (DOV) caught the attention of investors this week after its shares slipped another 0.5% in a single day, extending a downtrend that has been unfolding quietly but steadily over the past month. There was no headline-grabbing event behind this latest move. The drop appears to be a continuation of the market’s current lukewarm view on the stock rather than a direct reaction to fresh news. Still, Dover’s wide reach across industrial markets means that even drifting price action can reflect...
NasdaqGS:PLTR
NasdaqGS:PLTRSoftware

What the Latest Price Rally Means for Palantir After Strong Q1 Growth

If you are eyeing Palantir Technologies stock and wondering whether to hold, buy more, or maybe even cash out, you are not alone. This is a stock that has captured headlines, fan enthusiasm, and a fair dose of debate over its true worth. Over just the past three months, Palantir has delivered a 27.6% gain. At the one-year mark, that return increases to a notable 379%. Those numbers have many investors wondering if there is still more room to run or if the good news is already priced...
NYSE:VG
NYSE:VGOil and Gas

Assessing Venture Global After 14% Quarterly Surge and Strong Free Cash Flow Projections

If you are thinking about what to do with Venture Global stock right now, you are definitely not alone. With so many energy names under the spotlight, this one stands out—whether you are considering getting in, staying put, or perhaps trimming your position. The recent moves in the stock have certainly caught the market’s attention. Just in the last quarter, the price jumped over 14%. While there have been short-term pullbacks, including a 7.9% dip in the past week, VG still has some...
NYSE:LOMA
NYSE:LOMABasic Materials

Loma Negra (LOMA) Is Down 6.6% After Steep Drop in Q2 Earnings and Sales—Has the Bull Case Changed?

Loma Negra Compañía Industrial Argentina Sociedad Anónima recently reported its second quarter and six-month 2025 financial results, revealing ARS174.51 billion in quarterly sales and ARS397 million in net income, both lower than the prior-year period. An interesting detail is the steep year-on-year decline in basic earnings per share, from over ARS350 to ARS3.40 for the quarter, underscoring significant earnings pressure faced by the company. We'll examine how these sharply lower earnings...
NasdaqGS:REGN
NasdaqGS:REGNBiotechs

Regeneron (REGN): Assessing Valuation After FDA Postpones Key EYLEA HD Approval Decisions to Late 2025

Regeneron Pharmaceuticals (REGN) investors received news this week that the U.S. Food and Drug Administration has pushed back the target decision dates for two crucial EYLEA HD regulatory submissions to late 2025. This extension could delay the timeline for potential new approvals, adding more uncertainty to a product line that is central to Regeneron’s future business plans. Although this might seem like just another regulatory hurdle, the stakes are significant for those watching the...
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Does Exelixis Offer Value After Recent Stock Drop and Earnings Results?

If you are eyeing Exelixis and wondering if now is the right moment to get in, you are not alone. Plenty of investors are weighing the same question, especially after seeing the company deliver a solid one-year total return of nearly 47% and an even more impressive three-year gain of over 100%. While there has been some recent turbulence, with a roughly 15% dip over the past month, Exelixis remains up by more than 11% year to date. That kind of performance does not go unnoticed, and it...
NYSEAM:BKTI
NYSEAM:BKTICommunications

Uncovering 3 Undiscovered Gems In The US Market

As the United States market navigates a tech stock slump and anticipates insights from Federal Reserve Chair Jerome Powell, small-cap stocks may present unique opportunities amid broader market volatility. In this environment, identifying promising small-cap companies can be crucial for investors seeking diversification and potential growth, as these "undiscovered gems" often thrive by capitalizing on niche markets or innovative strategies.
NYSE:UGI
NYSE:UGIGas Utilities

How UGI's (UGI) New $300 Million Credit Facility May Reshape Its Capital Structure Strategy

On August 6, 2025, UGI Corporation amended its credit agreement to secure a new US$300 million senior secured revolving loan facility, enhancing its financial flexibility to address the conversion of its 2028 Notes and aligning with JPMorgan Chase Bank, N.A. as the administrative agent. This development signals UGI's proactive approach to managing upcoming debt obligations and reinforces its focus on liquidity and capital planning. We'll explore how securing this revolving loan facility...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

Vertex Pharmaceuticals (VRTX): Evaluating Valuation After Recent Modest Stock Movement

Vertex Pharmaceuticals (VRTX) has seen its stock tick up by nearly 1% today, catching the attention of investors who are watching for signals in a sector driven by both innovation and changing sentiment. While there is no headline event or major news announcement behind this move, modest fluctuations like this can sometimes prompt investors to reassess their conviction, especially after a period of drifting prices. With no clear trigger in play, the question becomes whether this recent...
NasdaqGS:MRX
NasdaqGS:MRXCapital Markets

Marex Group (NasdaqGS:MRX): Evaluating Value After Short Report Sparks Accounting and Legal Concerns

If you’re holding Marex Group (NasdaqGS:MRX) or considering an investment, the recent short report has likely caught your attention. Accusations regarding questionable off-balance sheet dealings and misleading disclosures have put Marex under scrutiny, raising challenging questions for investors about the reliability of its financial statements. With a shareholder rights law firm now investigating, an additional legal concern has emerged that is difficult to overlook. Marex has experienced...
NYSE:DBRG
NYSE:DBRGCapital Markets

Does DigitalBridge Group's Rare Negative Revenue This Quarter Reshape the Bull Thesis for DBRG?

On August 8, 2025, DigitalBridge Group reported second-quarter results showing negative revenue of US$3.21 million, a very large decline from the US$390.34 million reported a year earlier, and net income fell to US$31.62 million from US$91.42 million. This rare instance of negative revenue and lower profitability raises important questions about the company’s operational performance and the drivers behind such a shift year-over-year. We will explore how the company’s unexpected negative...
NYSE:NVR
NYSE:NVRConsumer Durables

Does NVR’s Recent Weak Earnings Signal a Pause or Opportunity for 2025 Investors?

Thinking about what to do with NVR stock right now? You are not alone. Whether you have watched it climb steadily through recent years or are just now considering an entry, NVR has a history of surprising investors. The past few months have put that on display, with the stock pulling back just over 9.9% in the past year, but not before delivering huge returns: nearly 87% over three years and more than 90% over five. Compared to many other players in homebuilding, that kind of long-term...
NasdaqGS:CRWD
NasdaqGS:CRWDSoftware

Does CrowdStrike Still Have Room to Grow After Its 54% Price Surge in 2025?

If you own, follow, or are simply curious about CrowdStrike Holdings, you are definitely not alone right now. The stock has been on quite a journey, sparking plenty of debate about what really comes next. Over just the past month, the price has taken an 11% dip, but if we zoom out a bit, things look much brighter. The stock is up an impressive 56.6% over the last year and a remarkable 257% over five years. This combination of recent pressure...